Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence

References

• Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T., & Jennings, L. W. (2010). Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138, 513–521, e511–516. doi:10.1053/j.gastro.2009.09.067
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban, S., Mohamed, M. K., Larouze, B., Carrat, F., & Valleron, A. J. (2006). Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. Journal of Hepatology, 44, 455–461. doi:10.1016/j.jhep.2005.08.008
   PubMed Web of Science ®Google Scholar
• ECAPMS. (2011). Average of weekly wages in public & private sectors. Retrieved May 10, 2012, from http://www.capmas.gov.eg/pdf/static/4-9-1.pdf
   Google Scholar
• Eckman, M. H., Talal, A. H., Gordon, S. C., Schiff, E., & Sherman, K. E. (2013). Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clinical Infectious Diseases, 56, 1382–1393. doi:10.1093/cid/cit069
   PubMed Web of Science ®Google Scholar
• El-Zanaty, F., & Way, A. (2009). Egypt Demographic and Health Survey 2008. Cairo: Ministry of Health (Egypt), El-Zanaty and Associates, Macro International.
   Google Scholar
• Fick, M., & Hirschler, B. (2014, March 21). Gilead offers Egypt new hepatitis C drug at 99 percent discount. Reuter. Retrieved from http://www.reuters.com/article/2014/03/21/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321
   Google Scholar
• Fink, S. A., & Jacobson, I. M. (2011). Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis. Nature Reviews Gastroenterology & Hepatology, 8, 285–295.
   PubMed Web of Science ®Google Scholar
• Frank, C., Mohamed, M. K., Strickland, G. T., Lavanchy, D., Arthur, R. R., Magder, L. S., … Sallam, I. (2000). The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 355, 887–891. doi:10.1016/S0140-6736(99)06527-7
   PubMed Web of Science ®Google Scholar
• FRED. (2014). Gross domestic product: Implicit price deflator. Federal Reserve Bank of St. Louis: Economic Research. Retrieved May 21, 2014, from http://research.stlouisfed.org/fred2/series/GDPDEF/
   Google Scholar
• Freeman, A. J., Dore, G. J., Law, M. G., Thorpe, M., Von Overbeck, J., Lloyd, A. R., … Kaldor, J. M. (2001). Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 34, 809–816. doi:10.1053/jhep.2001.27831
   PubMed Web of Science ®Google Scholar
• Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., … Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975–982. doi:10.1056/NEJMoa020047
   PubMed Web of Science ®Google Scholar
• Fung, V., Brand, R. J., Newhouse, J. P., & Hsu, J. (2011). Using medicare data for comparative effectiveness research: Opportunities and challenges. The American Journal of Managed Care, 17, 488–496.
   PubMedGoogle Scholar
• Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (1996). Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
   Google Scholar
• Hadziyannis, S. J., Sette, H., Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., … Ackrill, A. M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140, 346–355. doi:10.7326/0003-4819-140-5-200403020-00010
   PubMed Web of Science ®Google Scholar
• Hasan, F., Asker, H., Al-Khaldi, J., Siddique, I., Al-Ajmi, M., Owaid, S., … Al-Nakib, B. (2004). Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. The American Journal of Gastroenterology, 99, 1733–1737. doi:10.1111/j.1572-0241.2004.40077.x
   PubMed Web of Science ®Google Scholar
• IMF. (2014). Egypt: Gross domestic product per capita, current prices (U.S. dollars). Retrieved May 21, 2014, from http://www.imf.org/external/pubs/ft/weo/2014/01/weodata/weorept.aspx?sy=2012&ey=2019&scsm=1&ssd=1&sort=country&ds=.&br=1&pr1.x=60&pr1.y=5&c=469&s=NGDPDPC&grp=0&a=
   Google Scholar
• Jafferbhoy, H., Gashau, W., & Dillon, J. (2010). Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoeconomics and Outcomes Research, 2, 87–96.
   Google Scholar
• Kowdley, K. V., Lawitz, E., Crespo, I., Hassanein, T., Davis, M. N., DeMicco, M., … Jacobson, I. M. (2013). Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet, 381, 2100–2107. doi:10.1016/S0140-6736(13)60247-0
   PubMed Web of Science ®Google Scholar
• Lavanchy, D. (2009). The global burden of hepatitis C. Liver International, 29(Suppl 1), 74–81. doi:10.1111/j.1478-3231.2008.01934.x
   Web of Science ®Google Scholar
• Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., … Gane, E. J. (2013). Sofosbuvir for previously untreated chronic hepatitis C infection. The New England Journal of Medicine, 368, 1878–1887. doi:10.1056/NEJMoa1214853
   PubMed Web of Science ®Google Scholar
• Lehman, E. M., & Wilson, M. L. (2009). Epidemic hepatitis C virus infection in Egypt: Estimates of past incidence and future morbidity and mortality. Journal of Viral Hepatitis, 16, 650–658. doi:10.1111/j.1365-2893.2009.01115.x
   PubMed Web of Science ®Google Scholar
• Liu, S., Cipriano, L. E., Holodniy, M., & Goldhaber-Fiebert, J. D. (2013). Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One, 8(3), e58975. doi:10.1371/journal.pone.0058975
   Google Scholar
• Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., … Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958–965. doi:10.1016/S0140-6736(01)06102-5
   PubMed Web of Science ®Google Scholar
• Moyer, V. A. (2004). Summaries for patients. Screening for hepatitis C virus infection: Recommendations from the U.S. Preventive Services Task Force. Annals of Internal Medicine, 140, 62.
   Google Scholar
• OANDA Corporation. (2014). Historical exchange rates. Retrieved May, 21, 2014, from Historical Exchange Rates.
   Google Scholar
• Obach, D., Deuffic-Burban, S., Esmat, G., Anwar, W. A., Dewedar, S., Canva, V., … Yazdanpanah, Y. (2014). Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: The case of Egypt. Clinical Infectious Diseases, 58, 1064–1071. doi:10.1093/cid/ciu066
   PubMed Web of Science ®Google Scholar
• OPTN/SRTR, U. (2011). OPTN/SRTR 2009 Annual Report: Table 9.12b. Adjusted patient survival, living donor liver transplants survival at 3 months, 1 year, 5 years, and 10 years. Retrieved May 9, 2012, from http://optn.transplant.hrsa.gov/ar2009/912b_li.pdf
   Google Scholar
• Pawlotsky, J. M., Lonjon, I., Hezode, C., Raynard, B., Darthuy, F., Remire, J., … Dhumeaux, D. (1998). What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology, 27, 1700–1702. doi:10.1002/hep.510270632
   PubMed Web of Science ®Google Scholar
• Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 45, 529–538. doi:10.1016/j.jhep.2006.05.013
   PubMed Web of Science ®Google Scholar
• Piton, A., Poynard, T., Imbert-Bismut, F., Khalil, L., Delattre, J., Pelissier, E., … Opolon, P. (1998). Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology, 27, 1213–1219. doi:10.1002/hep.510270505
   PubMed Web of Science ®Google Scholar
• Plunkett, B. A., & Grobman, W. A. (2005). Routine hepatitis C virus screening in pregnancy: A cost-effectiveness analysis. American Journal of Obstetrics and Gynecology, 192, 1153–1161. doi:10.1016/j.ajog.2004.10.600
   PubMed Web of Science ®Google Scholar
• Rao, M. R., Naficy, A. B., Darwish, M. A., Darwish, N. M., Schisterman, E., Clemens, J. D., & Edelman, R. (2002). Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infectious Diseases, 2(1), 29. doi:10.1186/1471-2334-2-29
   PubMed Web of Science ®Google Scholar
• Ray, S. C., Arthur, R. R., Carella, A., Bukh, J., & Thomas, D. L. (2000). Genetic epidemiology of hepatitis C virus throughout Egypt. The Journal of Infectious Diseases, 182, 698–707. doi:10.1086/315786
   PubMed Web of Science ®Google Scholar
• Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., … Weinbaum, C. M. (2012). The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Annals of Internal Medicine, 156, 263–270. doi:10.7326/0003-4819-156-4-201202210-00378
   PubMed Web of Science ®Google Scholar
• Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., & Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30, 1299–1301. doi:10.1002/hep.510300504
   PubMed Web of Science ®Google Scholar
• Ruane, P. J., Ain, D., Riad, J., Meshrekey, R., Stryker, R., Wolfe, P., … Symonds, W. T. (2013). Sofosbuvir Plus Ribavirin in the Treatment of Chronic HCV Genotype 4 Infection in Patients of Egyptian Ancestry Conference Reports. 64rd Annual Meeting of the American Association for the Study of Liver Diseases. Retrieved from http://www.natap.org/2013/AASLD/AASLD_54.htm
   Google Scholar
• Sachs, J. D. (2001). Macroeconomics and health investing in health for economic development: Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization.
   Google Scholar
• Salomon, J. A., Weinstein, M. C., Hammitt, J. K., & Goldie, S. J. (2003). Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA, 290, 228–237. doi:10.1001/jama.290.2.228
   PubMed Web of Science ®Google Scholar
• Shepard, C. W., Finelli, L., & Alter, M. J. (2005). Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases, 5, 558–567. doi:10.1016/S1473-3099(05)70216-4
   PubMed Web of Science ®Google Scholar
• Singer, M. E., & Younossi, Z. M. (2001). Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. The American Journal of Medicine, 111, 614–621. doi:10.1016/S0002-9343(01)00951-2
   PubMed Web of Science ®Google Scholar
• Strickland, G. T. (2006). Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology, 43, 915–922. doi:10.1002/hep.21173
   PubMed Web of Science ®Google Scholar
• Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995). Clinical outcomes after transfusion-associated hepatitis C. The New England Journal of Medicine, 332, 1463–1466. doi:10.1056/NEJM199506013322202
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. (2014). International Data Base - Egypt, 2014. Retrieved May 21, 2014, from http://www.census.gov/population/international/data/idb/informationGateway.php
   Google Scholar
• USPSTF. (2004). Summaries for patients. Screening for hepatitis C virus infection: Recommendations from the U.S. Preventive Services Task Force. Annals of Internal Medicine, 140, 62.
   Google Scholar
• Wasley, A., & Alter, M. J. (2000). Epidemiology of hepatitis C: Geographic differences and temporal trends. Seminars in Liver Disease, 20(1), 1–16. doi:10.1055/s-2000-9506
   PubMed Web of Science ®Google Scholar
• WHO. (2010). Life Tables for WHO Member States, 1990, 2000, 2010 – by country and region. Geneva: World Health Organization.
   Google Scholar
• WHO. (2011). Hepatitis C. Fact sheet no. 164. Retrieved May 9, 2012, from http://www.who.int/mediacentre/factsheets/fs164/en/index.html
   Google Scholar
• World Bank. (2012). GDP deflator. Retrieved May 10, 2012, from http://data.worldbank.org/indicator/NY.GDP.DEFL.ZS
   Google Scholar